BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Future of Key Asset in Question as Gilead Reveals More Holds

  Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.

  February 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  Pfizer Alleges Stolen Trade Secrets at Heart of Regor Therapeutics Launch

  Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.

  February 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact

  The collaboration will focus on expanding targeted protein degradation therapies through the discovery of previously unrecognized molecular glues or monovalent degraders.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Lilly Delays Alzheimer’s Submission in Face of Proposed CMS Limitations

  The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.

  February 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID-19 Boosters Decrease Mortality by 97 Times and More News

  The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.

  February 3, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Voyager Lands Former Biogen Exec Al Sandrock

  Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.

  February 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Research Roundup: An Enzyme that May Prevent Autoimmune Diseases and More

  Research Roundup for February 4

  February 3, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial

  CRISPR Therapeutics and ViaCyte dosed their first patient in Phase I clinical trial of a novel gene-edited cell replacement therapy to treat Type 1 Diabetes.

  February 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Deals

  Intellia Broadens CRISPR Capabilities with Pick Up of Rewrite Therapeutics

  On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.

  February 3, 2022

   · 

  2 min read

   · 

  Claudia Beezhold
• 

  Business

  Mersana, Janssen Come Together in Potential $1B ADC Deal

  Janssen will provide its proprietary antibodies for research, while Mersana will contribute its proprietary Dolasynthem platform to target cancers with large unmet medical needs.

  February 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN